SEC Form 4 · accession 0001562180-18-004417

REGENXBIO Inc. · RGNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Vittal Vasista

Officer — Chief Financial Officer

Period of report

Nov 1, 2018

Accepted (ET)

Nov 5, 2018 · 4:20 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001590877

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 1, 2018	M	9,959	$3.76	A	147,242	D
Common Stock	Nov 1, 2018	M	9,718	$13.09	A	156,960	D
Common Stock^F2	Nov 1, 2018	S	19,677	$70.04	D	137,283	D
Common Stock	Nov 2, 2018	M	32,908	$13.09	A	170,191	D
Common Stock	Nov 2, 2018	M	20,833	$19.50	A	191,024	D
Common Stock^F3	Nov 2, 2018	S	53,741	$70.26	D	137,283	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4	$3.76	Nov 1, 2018	M	9,959	D	—	May 18, 2025	Common Stock	9,959	20,041	D
Employee Stock Option (Right to Buy)^F5	$13.09	Nov 1, 2018	M	9,718	D	—	Jan 27, 2026	Common Stock	9,718	65,282	D
Employee Stock Option (Right to Buy)^F5	$13.09	Nov 2, 2018	M	32,908	D	—	Jan 27, 2026	Common Stock	32,908	32,374	D
Employee Stock Option (Right to Buy)^F6	$19.50	Nov 2, 2018	M	20,833	D	—	Jan 3, 2027	Common Stock	20,833	29,167	D

Explanation of responses

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2This transaction was executed in multiple trades at prices ranging from $70.00 to $70.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $70.00 to $70.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4The previously granted option, representing a right to purchase a total of 30,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
F5The previously granted option, representing a right to purchase a total of 75,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
F6The previously granted option, representing a right to purchase a total of 50,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.